The effects of metformin on weight loss in women with gestational diabetes: a pilot randomized, placebo-controlled trial

Refuerzo, Jerrie; Viteri, Oscar A.; Hutchinson, Maria; Pedroza, Claudia; Tyson, Jon E.; Ramin, Susan M.

doi:10.1016/j.ajog.2014.12.019

Cited by 10 publications

(11 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metformin, an insulin sensitiser, has been trialled as an alternative to insulin treatment for gestational diabetes, with initial results indicating no effect on offspring blood pressure at 2 years of age in comparison to insulin treatment nor in maternal postpartum weight loss when compared to placebo (Battin et al, 2015;Refuerzo et al, 2015). There is currently a trial underway to test whether metformin administration during pregnancy in obese women will prevent macrosomia and this study will include investigation of maternal factors, including insulin resistance, inflammation and adiposity, as well as foetal adiposity (Chiswick et al, 2015).…”

Section: Candidate Programming Mechanisms and Factors In Maternal Obementioning

confidence: 99%

Developmental programming by maternal obesity in 2015: Outcomes, mechanisms, and potential interventions

Penfold

Ozanne

2015

Hormones and Behavior

View full text Add to dashboard Cite

This article is part of a Special Issue "SBN 2014". Obesity in women of child-bearing age is a growing problem in developed and developing countries. Evidence from human studies indicates that maternal BMI correlates with offspring adiposity from an early age and predisposes to metabolic disease in later life. Thus the early life environment is an attractive target for intervention to improve public health. Animal models have been used to investigate the specific physiological outcomes and mechanisms of developmental programming that result from exposure to maternal obesity in utero. From this research, targeted intervention strategies can be designed. In this review we summarise recent progress in this field, with a focus on cardiometabolic disease and central control of appetite and behaviour. We highlight key factors that may mediate programming by maternal obesity, including leptin, insulin, and ghrelin. Finally, we explore potential lifestyle and pharmacological interventions in humans and the current state of evidence from animal models.

show abstract

Section: Candidate Programming Mechanisms and Factors In Maternal Obementioning

confidence: 99%

Developmental programming by maternal obesity in 2015: Outcomes, mechanisms, and potential interventions

Penfold

Ozanne

2015

Hormones and Behavior

View full text Add to dashboard Cite

show abstract

“…Gradual administration of metformin, according to the severity of symptoms, can be used to adjust and to minimize the possible side effects. 18 The PCO is the most known risk for an exaggerated response to controlled ovarian stimulation (COH). The COH in women with PCOS may result in a significant number of follicles with a higher risk of ovarian hyperstimulation.…”

Section: Introductionmentioning

confidence: 99%

Impact of Metformin on IVF Outcomes in Overweight and Obese Women With Polycystic Ovary Syndrome: A Randomized Double-Blind Controlled Trial

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Metformin is also known to cross the placenta, and the long-term effects on the unborn child are still unknown [ 14 ]. In addition, metformin has some side-effects, such as gastrointestinal discomfort [ 15 , 16 ], and has been associated with depleted vitamin B12 status [ 17 ]. Another emerging treatment, sulfonylurea glyburide, carries similar unknowns [ 18 , 19 ].…”

Section: Introductionmentioning

confidence: 99%

The Effects of Myo-Inositol and B and D Vitamin Supplementation in the db/+ Mouse Model of Gestational Diabetes Mellitus

et al. 2017

View full text Add to dashboard Cite

Gestational diabetes mellitus (GDM) is a growing concern, affecting an increasing number of pregnant women worldwide. By predisposing both the affected mothers and children to future disease, GDM contributes to an intergenerational cycle of obesity and diabetes. In order to stop this cycle, safe and effective treatments for GDM are required. This study sought to determine the treatment effects of dietary supplementation with myo-inositol (MI) and vitamins B2, B6, B12, and D in a mouse model of GDM (pregnant db/+ dams). In addition, the individual effects of vitamin B2 were examined. Suboptimal B2 increased body weight and fat deposition, decreased GLUT4 adipose tissue expression, and increased expression of inflammatory markers. MI supplementation reduced weight and fat deposition, and reduced expression of inflammatory markers in adipose tissue of mice on suboptimal B2. MI also significantly reduced the hyperleptinemia observed in db/+ mice, when combined with supplemented B2. MI was generally associated with adipose tissue markers of improved insulin sensitivity and glucose uptake, while the combination of vitamins B2, B6, B12, and D was associated with a reduction in adipose inflammatory marker expression. These results suggest that supplementation with MI and vitamin B2 could be beneficial for the treatment/prevention of GDM.

show abstract

The effects of metformin on weight loss in women with gestational diabetes: a pilot randomized, placebo-controlled trial

Cited by 10 publications

References 21 publications

Developmental programming by maternal obesity in 2015: Outcomes, mechanisms, and potential interventions

Developmental programming by maternal obesity in 2015: Outcomes, mechanisms, and potential interventions

Impact of Metformin on IVF Outcomes in Overweight and Obese Women With Polycystic Ovary Syndrome: A Randomized Double-Blind Controlled Trial

The Effects of Myo-Inositol and B and D Vitamin Supplementation in the db/+ Mouse Model of Gestational Diabetes Mellitus

Contact Info

Product

Resources

About